NEJM with two early release articles. One by cardiologist Eric Topol, and the other questioning whether Celebrex and other COX-2’s have similar cardiovascular risk.
Related posts:
- Topol on Russert
- The left-leaning NEJM
- COURAGE trial: The NEJM strikes back
- Primary care: "Second class citizens"
- Does aspirin prevent fatal heart attack and stroke?
- Stents and the COURAGE trial
KevinMD.com on Facebook
Comments on this entry are closed.